



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:
IN01159KSERIAL NO.:
09/908,955APPLICANT:
SAKSENA, et alFILING DATE:
07/19/2001GROUP:
TBA

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
RB1	AD	WO 01 74768	10/11/01	WIPO				
RB1	AE	WO 01 40262	06/07/01	WIPO				
RB1	AF	WO 00 52032	09/08/00	WIPO				
RB1	AG	WO 99 07734	02/18/99	WIPO				
RB1	AH	WO 98 17679	04/30/98	WIPO				
	AI							
	AJ							
	AK							
	AJ							
	AK							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RB1	AL	WEI HAN, et al, "alpha-Ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors", <i>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS</i> , Vol. 10, No. 8, (2000), pp. 711-713.
RB1	AM	LLINAS-BRUNET MONTSE, et al, "Studies on the c-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease", <i>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS</i> , Vol. 8, No. 19, (1998), pp. 2719-2724.
	AN	
	AO	
	AP	
	AQ	

EXAMINER



DATE CONSIDERED

8-24-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1000

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
IN01159KSERIAL NO.:
09/908,955INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
SAKSENA, et alFILING DATE:
July 19, 2001GROUP:
To Be Assigned

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
RR	AA	U.S. 5,712,145			1	1	
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
RR	AC	WO 89/04669			1	1		
RR	AD	WO 98/17679			1	1		
RR	AE	WO 98/22496			1	1		
RR	AF	WO 98/07734			1	1		
RR	AG	WO 00/09558			1	1		
RR	AH	WO 00/09543			1	1		
RR	AI	EP 381 216			1	1		
RR	AJ							
RR	AK							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RR	AL	Pizzi, (1994) <i>Proc. Natl. Acad. Sci(USA)</i> 91:888-892
RR	AM	Failla (1996) <i>folding & Design</i> 1:35-42
RR	AN	Kollykhalov (1994) <i>J. Virol.</i> 68:7525-7533
RR	AO	Komoda (1994) <i>J. Virol.</i> 68:7351-7357
RR	AP	Landro (1997) <i>Biochem</i> 36:9340-9348
RR	AQ	Ingallinella (1998) <i>Biochem</i> 37:8906-8914
RR	AR	Llinas-Brunet (1998) <i>Bioorg. Med. Chem. Lett.</i> 8:1713-1718
RR	AS	Martin (1998) <i>Biochem</i> 37:11459-11468
RR	AT	Dimasi (1997) <i>J. Virol.</i> 71:7461-7469
RR	AU	Martin (1997) <i>Protein Eng.</i> 10:607-614
RR	AV	Elzouki (1997) <i>J. Hepat.</i> 27:42-48
RR	AW	<i>Bio World Today</i> 9(217): 4 (November 10, 1998)
RR	AX	Berenguer (1998) <i>Proc. Assoc. Am. Physicians</i> 110(2): 98-112
RR	AY	Hoofnagle (1997) <i>New England Journal Med.</i> 336:347
RR	AZ	Zhang (199) <i>Analytical Biochemistry</i> 270:268-275
RR	BA	Sali (1998) <i>Biochemistry</i> 3392-3401
RR	BB	Barlos (1991) <i>Int. J. Pept. Protein Res</i> 513-520
RR	BC	Holmberg (1979) <i>Acta Chem. Scand.</i> , B33:410-412
RR	BD	Agrawal(1999) <i>Hepatology Supplement to Vol 30</i> "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay"
RR	BE	Hughes (1992) <i>Org. Reactions</i> 42:335
RR	BF	Heck (1989) <i>Org. Reactions</i> 27:345-390
RR	BG	Han, (2000) <i>Bioorganic & Medicinal Chemistry Letters</i> 10 "α-Ketoamides, α-Ketoesters and α-Kiketones as HCV NS3 Protease Inhibitors" pp. 711-713.
RR	BH	Marchetti(1999) <i>Synlett</i> , Vol. S1, "Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease", pp 1000-1002.

EXAMINER

DATE CONSIDERED

R.K. Mon

8-24-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.